Abiopharma

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017372 Size: 7 KB

New Form 144 - GILEAD SCIENCES, INC. Filed: 2025-06-16 AccNo: 0001950047-25-004321 Size: 8 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017374 Size: 7 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017369 Size: 7 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017373 Size: 8 KB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000092 Size: 11 KB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000091 Size: 11 KB

Streamline Health® Reports Fiscal First Quarter 2025 Financial Results

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000090 Size: 12 KB

New Form 144 - BeOne Medicines Ltd. Filed: 2025-06-16 AccNo: 0001950047-25-004317 Size: 5 KB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000088 Size: 12 KB

New Form 144 - Evolus, Inc. Filed: 2025-06-16 AccNo: 0001950047-25-004315 Size: 11 KB